📈 69% of S&P 500 stocks beating the index - a historic record! Pick the best ones with AI.See top stocks

Eli Lilly doubles down on Irish operations with $1.8 bln Investment

Published 12-09-2024, 06:48 pm
© Reuters.
LLY
-

Investing.com -- Eli Lilly and Company (NYSE:LLY) on Thursday announced a $1.8 billion investment to expand its manufacturing operations in Ireland. 

This decision will enhance the production of biologic active ingredients, particularly for treatments targeting Alzheimer's disease and obesity.

The investment will be directed toward two major expansion projects in Ireland. The first of these is a $1 billion expansion at Lilly's Limerick site. 

This development will double the company's initial investment announced in March 2023, bringing the total commitment to a substantial $2 billion. 

Once complete, the Limerick facility will become a pivotal component in Lilly's global manufacturing network, focusing on producing biologic active ingredients for its recently approved Alzheimer’s treatment and other biologic medicines.

The expansion will introduce advanced technologies such as machine learning, artificial intelligence, and automated robotics to ensure precise and efficient manufacturing processes.

It will also generate 150 new high-skilled jobs, increasing the workforce at Limerick to 450 employees by the time production begins in 2026. 

The project is currently awaiting planning approval, with a formal application to be submitted to the Limerick City and County Council.

Simultaneously, Eli Lilly is investing $800 million to enhance its Kinsale facility, which began operations last year. 

"Investment in these two locations in Ireland (Limerick & Kinsale) shows Lilly's work is not done -- even if US drug shortages seem to calm down, the expectation of high, ongoing demand remains," said analysts at BMO Capital Markets in a note.

This expansion will bolster the facility’s capacity to meet the growing demand for medications addressing diabetes and obesity. 

The Kinsale site employs a digital-first approach and continuous manufacturing technology to produce complex peptides. It also boasts the largest privately owned solar farm in Ireland, which supplies a significant portion of the facility’s power. 

“These investments will boost the production of some of our medicines, helping millions of people with diabetes, obesity and Alzheimer's disease live the healthiest lives possible," said Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations

Additionally, Lilly’s Global Business Solutions center in Cork has seen growth, with employment levels expected to exceed 2,000 by the end of 2024, underscoring the company’s ongoing investment in Ireland.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.